Back to top

Tale of the Tape

Zacks Equity Research

Falling Earnings Estimates Signal Weakness Ahead for Amedisys (AMED)
November 14, 2016

AMED ADUS

Trades from $3

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Amedisys Inc. (AMED - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in AMED.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 6 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from $1.71 a share a month ago to its current level of $1.50.

Also, for the current quarter, Amedisys has seen 6 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to 40 cents a share from 51 cents over the past 30 days.    

The stock also has seen some pretty dismal trading lately, as the share price has dropped 9.7% in the past month.

AMEDISYS INC Price and Consensus

 

AMEDISYS INC Price and Consensus | AMEDISYS INC Quote

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical-Outpatient/Home Care industry, you may instead consider a better-ranked stock - Addus HomeCare Corporation (ADUS - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AMEDISYS INC (AMED) - free report >>

ADDUS HOMECARE (ADUS) - free report >>